CJC-1295 vs PEG-MGF
Side-by-Side Comparison
| Attribute | Cjc 1295 | Peg Mgf |
|---|---|---|
| Category | Growth Hormone Secretagogue | Muscle & Performance |
| Mechanism | CJC-1295 binds to GHRH receptors (GHRHR) on pituitary somatotroph cells, activating intracellular cAMP signaling to stimulate both the transcription of the GH gene and pulsatile release of endogenous... | MGF is produced from the IGF-1 gene by alternative splicing of exons 4, 5, and 6. The unique C-terminal E domain of MGF (24 amino acids in the Ec splice variant) is responsible for its distinct... |
| Evidence Rating | D — Preclinical | D — Preclinical |
| Clinical Status | Research-only / Not approved for human use | Research-only. No human clinical trials registered or completed. Preclinical characterization primarily in cell culture and rodent models. |
| Safety Profile | Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief; Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) | No human clinical trials — safety profile is entirely unknown; No formal toxicology studies published for PEG-MGF |
| Molecular Weight | No DAC: ~3367.9 g/mol; With DAC: ~3647.3 g/mol | ~2,867 g/mol (peptide portion); total MW depends on PEG chain size |
| Half-Life | No DAC (mod GRF 1-29): ~30 min; With DAC: ~8 days | Native MGF: minutes; PEG-MGF: estimated several hours (no published human PK data) |
Overview
CJC-1295 and PEG-MGF are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
CJC-1295 — Mechanism & Evidence
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) originally developed by ConjuChem Technologies for HIV-associated lipodystrophy. It exists in two forms: with DAC (Drug Affinity Complex) for extended half-life of 5.8-8.1 days, and without DAC (Mod GRF 1-29) for shorter, pulsatile release with a half-life of approximately 30 minutes. Two 2006 randomized, placebo-controlled, double-blind clinical trials (Teichman et al.) demonstrated dose-dependent GH increases of 2-10 fold and IGF-1 increases of 1.5-3 fold in healthy adults aged 21-61. The No DAC version is generally considered the safer choice due to its physiological pulsatile pattern.
Key claims: Increases growth hormone and IGF-1; Improves body composition; Promotes deep sleep.
PEG-MGF — Mechanism & Evidence
PEG-MGF (Pegylated Mechano Growth Factor) is a synthetic, PEGylated form of the C-terminal peptide of mechano growth factor (MGF), a splice variant of the IGF-1 gene (IGF-1Ec in humans, IGF-1Eb in rodents). Native MGF is expressed locally in skeletal muscle immediately following mechanical overload or damage (e.g., resistance exercise). It stimulates muscle satellite cell (stem cell) activation and proliferation, initiating the early repair response before the sustained IGF-1Ea isoform takes over for differentiation. Because native MGF has an extremely short half-life (minutes), PEGylation (conjugation with polyethylene glycol) protects the peptide from enzymatic degradation, extending systemic circulation. PEG-MGF is used in the bodybuilding community for localized muscle growth. It is prohibited by WADA and not approved for human therapeutic use.
Key claims: Activates muscle satellite cells for repair; Promotes muscle hypertrophy; PEGylation extends duration of action.
Shared Research Applications
Both peptides are studied for: Body Composition.
CJC-1295 is also researched for: Anti-Aging.
PEG-MGF is also researched for: Injury Recovery.
Safety Considerations
CJC-1295: Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) Water retention and edema (dose-dependent; elevated GH causes sodium/water retention via kidneys)
PEG-MGF: No human clinical trials — safety profile is entirely unknown No formal toxicology studies published for PEG-MGF Theoretical oncogenic risk: satellite cell proliferation and IGF-1 pathway activation are relevant to cancer biology
Related Products
Related Research News
CJC-1295 with DAC and Ipamorelin: Growth Hormone Research Guide
CJC-1295 with DAC and Ipamorelin represent key compounds in growth hormone research, targeting distinct pathways for GH and IGF-1 signaling. CJC-1295 with DAC acts as a long-acting GHRH analogue with a half-life of 5.8 to 8.1 days, while Ipamorelin functions as a selective growth hormone secretagogue via the ghrelin receptor. Together, they support studies on metabolism, recovery, and body composition.
CJC-1295 + Ipamorelin: Growth Hormone Stack Mechanics
CJC-1295 and Ipamorelin form the most studied growth hormone peptide combination in research. They target separate receptor pathways to boost GH secretion through the somatotropic axis. This stack produces amplified GH pulses, with preclinical data showing 3 to 5 times baseline levels versus 1.5 to 2 times alone.
Ipamorelin: Selective GH Secretagogue for Clean Pulsatile Release
Ipamorelin, a third-generation GHS-R1a agonist (CAS 170851-70-4), stimulates pulsatile growth hormone release without elevating cortisol or prolactin, unlike earlier GHRPs. This selectivity supports precise research into GH axis effects, IGF-1 pathways, body composition, recovery, and sleep. Studies highlight its role in anabolic processes and synergy with CJC-1295 for enhanced GH output.